Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - terazosin hydrochloride - oral tablet - 10mg

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - terazosin hydrochloride - oral tablet - 10mg

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - terazosin hydrochloride - oral tablet - 2mg

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

zanza specials international ltd - terazosin hydrochloride - oral tablet - 2mg

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

zanza specials international ltd - terazosin hydrochloride - oral tablet - 10mg

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix healthcare distribution ltd - terazosin hydrochloride - oral tablet - 2mg

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix healthcare distribution ltd - terazosin hydrochloride - oral tablet - 10mg

Izraelis - anglų - Ministry of Health

teva pharmaceutical industries ltd, israel - terazosin as hydrochloride dihydrate - tablets - terazosin as hydrochloride dihydrate 5 mg - terazosin - terazosin - for symptomatic treatment of urinary obstructon caused by benign prostatic hyperplasia (bph). for mild to moderate hypertension.

Izraelis - anglų - Ministry of Health

teva pharmaceutical industries ltd, israel - terazosin as hydrochloride dihydrate - tablets - terazosin as hydrochloride dihydrate 2 mg - terazosin - terazosin - for symptomatic treatment of urinary obstructon caused by benign prostatic hyperplasia (bph). for mild to moderate hypertension.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

preferred pharmaceuticals, inc - terazosin hydrochloride (unii: d32s14f082) (terazosin - unii:8l5014xet7) - terazosin 1 mg - terazosin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (bph). there is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of bph when treated with terazosin capsules. the long-term effects of terazosin capsules on the incidence of surgery, acute urinary obstruction or other complications of bph are yet to be determined. terazosin capsules are also indicated for the treatment of hypertension. terazosin capsules can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents. terazosin capsules are contraindicated in patients known to be hypersensitive to terazosin hydrochloride.